Novel antithrombotic approaches to coronary artery disease

The American Journal of Cardiology

Volumn 75, Issue 6 SUPPL. 1, 1995, Pages 27B-33B

  Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; DESULFATOHIRUDIN; EFEGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; RO 4483; STREPTOKINASE; THROMBIN INHIBITOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

ANTITHROMBINS; ASPIRIN; COMPARATIVE STUDY; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HEPARIN; HUMAN; PLASMINOGEN ACTIVATORS; PLATELET AGGREGATION INHIBITORS;

EID: 0028922945     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(95)80007-F     Document Type: Article

References (24)

1. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
2. Abrupt vessel closure
3. Clinical trials of platelet receptor inhibitors
4. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
5. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of restenosis results at six months
6. Outcome of patients treated with the GPIIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study
7. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
8. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
9. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI 6 trials
10. HIT (Hirudin for the Improvement of Thrombolysis): results of a dose escalation study
11. Recombinant hirudin for unstable angina pectoris
12. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
13. PTCA with hirudin associated with less acute cardiac complications that with heparin
14. Safety and efficacy of hirulog in patients with unstable angina
15. Initial experience with a direct antithrombin, hirulog, in unstable angina
16. The effect of a new thrombin inhibitor (argatroban) in the prevention of reocclusion after reperfusion therapy in patients with acute myocardial infarction
17. Reversible tripeptide thrombin inhibitors as adjunctive agents in coronary thrombosis: a comparison with heparin in a canine model of coronary artery thrombosis
18. Combination of platelet fibrinogen receptor antagonist and direct antithrombin inhibitor at low doses markedly improves thrombolysis
19. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
20. The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction
21. Double bolus of r-PA in the dosage finding
22. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
23. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator